PF-Atlas › Clinical Trials › NCT04525547

Safety and Effectiveness of Nintedanib in Korean Patients

Nintedanib · Not specified

Registry ID
NCT04525547
Phase
Not specified
Status
Completed
Drug / intervention
Nintedanib
Sponsor
Boehringer Ingelheim
Start
2021-01-13

About this trial

Nintedanib is evaluated in NCT04525547, a idiopathic pulmonary fibrosis study sponsored by Boehringer Ingelheim. Current status: Completed.

View NCT04525547 on ClinicalTrials.gov →

Explore related

All Nintedanib trialsAll IPF trials

Related trials

nintedanib — NCT02606877Nintedanib — NCT02598193Nintedanib — NCT02579603Nintedanib — NCT02597933Nintedanib — NCT02999178Nintedanib — NCT02607722
Medical disclaimer. This page summarizes public trial data for NCT04525547 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.